Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastric or Gastroesophageal Junction Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT05322577
What this trial is testing

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Amgen 72
Large-scale testing (Phase 3)Looking for participantsNCT07221149
What this trial is testing

Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Who this might be right for
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb 690
Testing effectiveness (Phase 2)UnknownNCT00865982
What this trial is testing

Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer

Who this might be right for
Gastric CancerEsophageal Cancer
Charite University, Berlin, Germany 50
Testing effectiveness (Phase 2)Study completedNCT00107341
What this trial is testing

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Who this might be right for
Esophageal Cancer
Alliance for Clinical Trials in Oncology 37
Large-scale testing (Phase 3)Study completedNCT03675737
What this trial is testing

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

Who this might be right for
Stomach Neoplasms
Merck Sharp & Dohme LLC 1,579
Not applicableUnknownNCT04891900
What this trial is testing

TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric CancerAdenocarcinoma of Esophagogastric Junction
Henan Cancer Hospital 25
Testing effectiveness (Phase 2)UnknownNCT04202601
What this trial is testing

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Who this might be right for
Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Peking University 80
Testing effectiveness (Phase 2)WithdrawnNCT03704077
What this trial is testing

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric CancerCancer of the StomachStomach Cancer+1 more
Bristol-Myers Squibb
Large-scale testing (Phase 3)Looking for participantsNCT06177041
What this trial is testing

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Who this might be right for
Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd 486
Testing effectiveness (Phase 2)Active Not RecruitingNCT05190445
What this trial is testing

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Who this might be right for
HER2-positive Gastric Cancer
Pieris Pharmaceuticals, Inc. 80
Large-scale testing (Phase 3)Study completedNCT05568095
What this trial is testing

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

Who this might be right for
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Arcus Biosciences, Inc. 1,040
Testing effectiveness (Phase 2)Study completedNCT01503983
What this trial is testing

Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive

Who this might be right for
Stage IV Gastric Cancer With Metastasis
Fundación para el Progreso de la Oncología en Cantabria 45
Testing effectiveness (Phase 2)Looking for participantsNCT06766305
What this trial is testing

QL1706 Combined With SOX Used in Theperioperative Treatment

Who this might be right for
Gastric CancersEsophagogastric Junction Cancers
Xiangdong Cheng 54
Large-scale testing (Phase 3)Looking for participantsNCT07385703
What this trial is testing

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. 752
Testing effectiveness (Phase 2)Study completedNCT07460596
What this trial is testing

Concentrated Complex Plant Dietary Elements for Chemotherapy-Induced Diarrhea

Who this might be right for
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal CarcinomaColon and Rectal Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Study completedNCT00253370
What this trial is testing

Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionMetastatic Gastric CancerAdvanced Unresectable Gastric Cancer
National Cancer Institute (NCI) 44
Not applicableUnknownNCT03045770
What this trial is testing

MFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Who this might be right for
Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction
Fujian Cancer Hospital 150
Testing effectiveness (Phase 2)Ended earlyNCT00848783
What this trial is testing

Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers

Who this might be right for
Gastric CancerGastric AdenocarcinomaEsophageal Cancer
NYU Langone Health 8
Testing effectiveness (Phase 2)Looking for participantsNCT06005493
What this trial is testing

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Gastric CancerGastro-esophageal Junction CancerPancreatic Ductal Adenocarcinoma+1 more
AstraZeneca 392
Large-scale testing (Phase 3)Active Not RecruitingNCT06346392
What this trial is testing

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
AstraZeneca 594
Next Page